




Website Update 2011

John-Michael Maas

Information is everywhere.

Where is the information?

The information is in all of you.





TB R&D Weekly Update: Podcast Interview with Dr. Sanjib Bhakta

This week's interview is with Dr. Sanjib Bhakta who is Head of Mycobacteria Research Laboratory, Microbiology, Department of Biological Sciences, Institute of Structural and Molecular Biology at the Birbeck University of London. Dr. Bhakta's Laborat...

[Listen](#)

[View All Podcasts »](#)

MESSAGES TO OUR MEMBERS

Going to Lille? Don't Miss the WGND Annual Meeting and other events!
For more information, click here.

Check out our design for new Clinical Trials Database!

The WGND is developing a series of databases to assist tuberculosis clinical trials. Click "Clinical Research" in nav.

[View All Messages »](#)

FROM THE BLOG



K-RITH Seeking Top Recruits for Research Institute in South Africa

K-RITH invites applications from qualified scientists to serve as assistant, associate, and full investigators. Candidates should be interested in tuberculosis and HIV, and we are seeking scientists with a broad variety of backgrounds. The deadline for filing applications for this round of recruitment is November 1.

Posted 14 October 2011 | [No Comments](#)



Winstone's Voice

As has been widely reported, we lost Winstone Zulu, a tireless advocate for TB/HIV. Chief among his gifts was the ability to speak with passion about his subject, finding the precise balance between hard facts, personal history, and an inspiring call to action.

Posted 12 October 2011 | [One Comment](#)

GET INVOLVED



SITE FEATURES



Global Discovery Programs

An online tool that invites developers to submit their discovery programs so we can provide a more complete snapshot of current global efforts.

[View Discovery](#)



Why We Need New TB Drugs

Today's TB drug regimen takes too long to be effective and requires too many medications. Treatment of drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even lengthier, taking 18-24 months or longer.

[Read More](#)

ABOUT US



Our Mission

To accelerate the discovery and development of new drugs for the treatment of tuberculosis by bringing together the stakeholders in TB Drug Development, including the patients themselves.

[Read More »](#)



Global Members

The WGND is composed of diverse interested stakeholders in TB drug development, including those working in TB drug R&D, regulators, public health workers, funders, community representatives, advocates and policy-makers.

[Read More »](#)

Total members: **197**

WGND Members:

William Bishai
Johns Hopkins School of Medicine

[View All Members »](#)

Evolving to an information sharing platform

Blog feed on the homepage
Video / Podcast promotion

Messages to members

Get involved

Social media

Whole site has been redesigned with further rollouts through Q1 2012.


Total members: **197**

up from 145 last year

Contacts

434 ACTIVE CONTACTS

 [Add and update contacts](#)

 [Grow my contact list](#)

hard facts, personal history, and an inspiring call to action.

Posted: 12 October 2011 | One Comment

Drug-sensitive disease requires 6-9 months whereas treatment of drug-resistant TB is even longer, taking 18-24 months or longer.



Total members:

World Members:

William Bishai

John Hopkins School

[View All Members >](#)


©2011 Working Group on New TB Drugs. All Rights Reserved.

Site by

[About](#) | [Contact Us](#)

The Working Group is Supported by

PERIOD: YTD



ANALYTICS

Strong user growth

- Sustained audience (peaks with communications)
- Audience growth
- Positive response to site enhancements
- Rising search traffic (58% last month)
- Time on site remains strong (4:00 since launch of new site)




PIPELINE

[Login/Register to add a Project](#)

[Download the PPT Slide](#)


CLINICAL DEVELOPMENT





The Pipeline – Pre/Clinical

No drop outs
2 advanced to Phase II
1 advanced to Phase III



DISCOVERY PIPELINE



HIT-TO-LEAD

LEAD-OPTIMIZATION

Phenotypic Hit-to-Lead

University of Illinois, TB Alliance

M. tuberculosis Protein Kinase Inhibitors

Several chemical scaffolds with various PknA, PknB and PknG selectivity profiles
Vertex Pharmaceuticals, Incorporated

Fungal metabolites

Mycosynthetix, University of Illinois at Chicago

Actinomycete metabolites

University of Illinois at Chicago, Myongji University

DNA metabolism

Novel structural class
AstraZeneca R and D Bangalore

Phenotypic hit to lead

Multiple novel structural classes
Lilly TB Drug Discovery Initiative

Novel hit-lead programs

Novel structural class
Lilly TB Drug Discovery Initiative

Phenotype Hit-to-Lead

Novel structural classes
AstraZeneca R and D Bangalore

Combinatorial Biosynthetic Compounds

Shaw Environmental and University of Illinois at Chicago

Folate Biosynthesis Inhibitors

AstraZeneca, TB Alliance

Phenotypic Hit-to-Lead

GlaxoSmithKline, TB Alliance

Malate Synthase Inhibitors

GlaxoSmithKline, Texas A&M University, TB Alliance

Menaquinone Synthase Inhibitors

Colorado State University, TB Alliance

Inhibitors of Mycobacterium Tuberculosis Energy Metabolism

Various Classes
UPenn and TB Alliance

Inhibitors of isopenoid biosynthesis

Lilly TB Drug Discovery Initiative

Protein Splicing Inhibitors

Boston Biomedical Research Institute

Nitroimidazoles

Nitroimidazoles
TB Alliance, University of Auckland, University of Illinois

Diarylquinolines

Diarylquinoline
TB Alliance, University of Auckland, Tibotec

Riminophenazines

Riminophenazines antibiotic
TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois

InhA inhibitors

Novel structural class
GlaxoSmithKline, TB Alliance

LeuRS inhibitors

Oxaboroles
Anacor Pharmaceuticals

Mycobacterial Gyrase Inhibitors

Novel structural class
TB Alliance, GlaxoSmithKline

Pyrazinamide Analogs

Pyrazinamide/nicotinamide analogs
TB Alliance/Yonsei University

TL1 Inhibitors

Capuramycins
Sequella

MTopo

Novel structural class
AstraZeneca R and D Bangalore

GyrB Inhibitors




AstraZeneca, TB Alliance

SCAR - Ruthenium (II) phosphine/diimine/picolinate complexes: Inorganic compounds as agents against tuberculosis

Inorganic Compounds
FAPESP/Brazil

Spectinomides

Spectinomycin analogs
St Jude Children's Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbiotix

Explore. Learn. Join the conversation. Follow us on:   

WORKING GROUP
ON NEW TB DRUGS

Stop TB Partnership

Blog Pipeline Clinical Research Resources Meetings About Us

Discovery Pipeline Pipeline Add a Project View Previous Pipelines Register/Log in to Pipeline

DISCOVERY PIPELINE

[Login/Register to add a Project](#) [Download the PPT Slide](#)

HIT-TO-LEAD		LEAD-OPTIMIZATION	
Phenotypic Hit-to-Lead University of Illinois, TB Alliance M. tuberculosis Protein Kinase Inhibitors Several chemical scaffolds with various PknB, PknG and PknK selectivity profiles Vertex Pharmaceuticals, Incorporated Fungal metabolites MycoPharma, University of Illinois at Chicago Actinomycete metabolites University of Illinois at Chicago, Myungi University DNA metabolism Novel structural class AstraZeneca R and D Bangalore Phenotypic hit to lead Multiple novel structural classes Lilly TB Drug Discovery Initiative Novel hit-to-lead programs Novel structural class Lilly TB Drug Discovery Initiative Phenotypic Hit-to-Lead Novel structural classes AstraZeneca R and D Bangalore	Combinatorial Biosynthetic Compounds Shaw Environmental and University of Illinois at Chicago Folate Biosynthesis Inhibitors AstraZeneca, TB Alliance Phenotypic Hit-to-Lead GlaxoSmithKline, TB Alliance Mutate Synthase Inhibitors GlaxoSmithKline, Texas A&M University, TB Alliance Menaquinone Synthase Inhibitors Colorado State University, TB Alliance Inhibitors of Mycobacterium Tuberculosis Energy Metabolism Various Classes UPenn and TB Alliance Inhibitors of isoprenoid biosynthesis Lilly TB Drug Discovery Initiative Protein Splicing Inhibitors Boston Biomedical Research Institute	Nitroimidazoles Nitroimidazole TB Alliance, University of Auckland, University of Illinois Diarylequinolines Diarylequinoline TB Alliance, University of Auckland, Teatex Riminothiazines Benzimidazole derivative TB Alliance, Institute of Materia Medica, The Beijing Tuberculosis and Thoracic Tumor Research Institute and University of Illinois isNA Inhibitors Novel structural class GlaxoSmithKline, TB Alliance LauRS Inhibitors Oxaboroles Anacor Pharmaceuticals Mycobacterial Gyrase Inhibitors Novel structural class TB Alliance, GlaxoSmithKline	Pyrazinamide Analogs Pyrazinamide/oxamamide analogs TB Alliance/Yonsei University TL1 Inhibitors Capreomycin Seqella MTopo Novel structural class AstraZeneca R and D Bangalore GyrB Inhibitors AstraZeneca, TB Alliance SCAR - Ruthenium (II) phosphine/diimine/picolinate complexes as agents against tuberculosis Inorganic Compounds FAPESP/Brazil Spectinomides Spectinomycin analogs St. Jude Children's Research Hospital, University of Tennessee Health Science Center, Colorado State University, University of Zurich, Microbetta

©2011 Working Group on New TB Drugs. All Rights Reserved. Site by Darby Communications


About Contact Us

The Working Group is Supported by **Stop TB Partnership**

The Pipeline – Discovery

No drop outs
4 new hit-to-lead
3 new lead-optimization

2010 2011

21  **28**

compounds compounds

Coming Soon: **WGND Clinical Trials Database** newtbdrugs.org/clinical



Four main components:

- Registration Clinical Trial Sites
- Other TB Clinical Trial Sites
- New Concepts
- List of TB Drug Trials



CLINICAL TRIALS » REGISTRATION READY SITES

Filter By Keyword

Filter By Attributes

- Certified Microbiology Lab
- Pediatric
- MDR
- HIV/TB

Filter By Country

-- Select --

Programme National contre la Tuberculose - Laboratoire de Référence des Mycobactéries

Cotonou, Benin

Gaborone Prevention/Treatment Trials CRS 12701

Gaborone, Botswana

Molepolole Prevention/Treatment Trials CRS (Molepolole PTT CRS) 12702

Molepolole, Botswana

Hospital Nossa Senhora da Conceicao CRS 12201

Porto Alegre, Brazil

Hospital Universitario Clementino Fraga Filho

Rio de Janeiro, Brazil

Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS 12101

Rio de Janeiro, Brazil

Universidade Federal do Espirito Santo/HUCAM

Vitoria, Brazil

Montreal Chest Institute McGill University

Montreal, Canada

Beijing Tuberculosis and Thoracic Tumor Research Institute

Beijing, China

CRS Beijing China

Beijing, China

Beijing Chest Hospital

Beijing, China

New Resource: CLINICAL TRIALS » REGISTRATION CLINICAL TRIAL SITES

Status:

Built

Integrating data
(complete Q4 2011)

Development partners:
Andrew Vernon / CDC,
Barbara Laughon / NIH/NIAID
and CPTR

CLINICAL TRIALS » REGISTRATION READY SITES

Filter By Keyword

Filter By Attributes

Certified Microbiology Lab

Pediatric

MDR

HIV/TB

Filter By Country

-- Select --

Programme National contre la Tuberculose - Laboratoire de Référence des Mycobactéries
Cotonou, Benin

Gaborone Prevention/Treatment Trials CRS 12701
Gaborone, Botswana

Molepolole Prevention/Treatment Trials CRS (Molepolole PTT CRS) 12702
Molepolole, Botswana

Hospital Nossa Senhora da Conceicao CRS 12201
Porto Alegre, Brazil

Hospital Universitario Clementino Fraga Filho
Rio de Janeiro, Brazil

Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS 12101
Rio de Janeiro, Brazil

Universidade Federal do Espirito Santo/HUCAM
Vitoria, Brazil

Montreal Chest Institute McGill University
Montreal, Canada

Beijing Tuberculosis and Thoracic Tumor Research institute
Beijing, China

CRS Beijing China
Beijing, China

Beijing Chest Hospital
Beijing, China

Filtering results:

Filter By Keyword

Filter By Attributes

Certified Microbiology Lab

Pediatric

MDR

HIV/TB

Filter By Country

-- Select --

Click a site name to view details:



CLINICAL TRIALS » REGISTRATION READY SITES

[Submit a Site to the Database](#)

[Return to Registration Ready Sites Overview](#)

Shanghai Pulmonary Hospital (Shanghai, China)

Last Updated: 11-Nov-2010

SITE INFORMATION

Address:

No. 507 Zhengmin Road
Yangpu District
Shanghai, China
[view their website](#)

Site Leader:

Dr. Heping Xiao
[email](#)

Community / Advocacy Contact:

Zhang Min
[email](#)

SITE PARTICULARS

Number of patients enrolled in a registration quality trial over the last 24 months: **100**
Certified lab with MGIT & LJ culture: **Yes**

Patients Available		
Pediatric	MDR	HIV/TB
Yes	Yes	Yes

Clinical Trials Experience

TRIAL NAME	NETWORK / CTU / PI	# PATIENTS	SPONSOR	SPONSOR CONTACT	NCT#	OTHER REGISTRATION LINKS
C-001-402	Info goes here	600	Sponsor Name	Contact Name email	NCT00398931	WHO6789
C-001-403	Info goes here	600	Sponsor Name	Contact Name email	NCT00398931	WHO6789

External Reference Links

[TB Alliance Site Eval Link](#)
[TBTC Site Eval Link](#)

Related Links and Publications

[Publication Number One](#)
[Another Pub](#)

Downloads

[Download Name Link](#)
[Another Download Name Link](#)

ADDITIONAL COMMENTS

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sit amet dolor tristique erat cursus cursus. Aliquam aliquet feugiat metus a mollis. Donec porta malesuada quam. Sed nec risus consequat enim aliquet tincidunt eu sit amet erat. Fusce pulvinar felis ut dui euismod ornare. Etiam congue laoreet vulputate. Praesent adipiscing elementum tincidunt. Donec ultrices lacinia dictum. Suspendisse gravida, lorem id fermentum consectetur, uma mi vehicula tellus, consequat suscipit velit nisi id massa. In faucibus, dolor vel vestibulum lobortis, sem metus tincidunt odio, nec viverra tortor sapien et eros.

CLINICAL TRIALS » NEW CONCEPTS

[Return to the New Concepts Overview](#)

Study Name (Study #)

Last Updated: 11-Nov-2010



OVERVIEW

PI / Study Chair
Dr. Ramesh Prashanth

Network / CTU / PI
TBTC

Current Study Status
Enrolling

Target Accrual
1,250

Downloads

[Study Protocol \(pdf - 276kb\)](#)
[Concept Summary \(doc - 1276kb\)](#)

PROTOCOL SYNOPSIS

PHASE	STUDY TYPE	INTERVENTION TYPE	POPULATION
Phase I	RX	Diagnostic	Pediatric

TRIAL DESIGN

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sit amet dolor tristique erat cursus cursus. Aliquam aliquet feugiat metus a mollis. Donec porta malesuada quam. Sed nec risus consequat enim aliquet tincidunt eu sit amet erat. Fusce pulvinar felis ut dui euismod ornare. Etiam congue laoreet vulputate. Praesent adipiscing elementum tincidunt. .

RATIONALE

Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sit amet dolor tristique erat cursus cursus. Aliquam aliquet feugiat metus a mollis. Donec porta malesuada quam. Sed nec risus consequat enim aliquet tincidunt eu sit amet erat. Fusce pulvinar felis ut dui euismod ornare. Etiam congue laoreet vulputate. Praesent adipiscing elementum tincidunt. Donec ultrices lacinia dictum. Suspendisse gravida, lorem id fermentum consectetur, urna mi vehicula tellus, consequat suscipit velit nisi id massa. In faucibus, dolor vel vestibulum lobortis, sem metus tincidunt odio, nec viverra tortor sapien et eros.

COMPARISON GROUPS

- Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sit amet dolor tristique erat cursus cursus. Aliquam aliquet feugiat metus a mollis. Donec porta malesuada quam.
- Sed nec risus consequat enim aliquet tincidunt eu sit amet erat. Fusce pulvinar felis ut dui euismod ornare. Etiam congue laoreet vulputate.
- Praesent adipiscing elementum tincidunt. Donec ultrices lacinia dictum. Suspendisse gravida, lorem id fermentum consectetur, urna mi vehicula tellus, consequat suscipit velit nisi id massa. In faucibus, dolor vel vestibulum lobortis, sem metus tincidunt odio, nec viverra tortor sapien et eros.

PRIMARY ENDPOINTS

- Lorem ipsum dolor sit amet, consectetur adipiscing elit. In sit amet dolor tristique erat cursus cursus. Aliquam aliquet feugiat metus a mollis. Donec porta malesuada quam.
- Sed nec risus consequat enim aliquet tincidunt eu sit amet erat. Fusce pulvinar felis ut dui euismod ornare. Etiam congue laoreet vulputate.
- Praesent adipiscing elementum tincidunt. Donec ultrices lacinia dictum. Suspendisse gravida, lorem id fermentum consectetur, urna mi vehicula tellus, consequat suscipit velit nisi id massa. In faucibus, dolor vel vestibulum lobortis, sem metus tincidunt odio, nec viverra tortor sapien et eros.

New Resource: CLINICAL TRIALS » NEW CONCEPTS

Status:
Design complete
Under construction (Q1 2012)

Development partners:
Andrew Vernon / CDC &
Barbara Laughon / NIH/NIAID
and CPTR

CLINICAL TRIALS » TB DRUG TRIALS

Download
The Full Database

Submit a Site
to the Database

Filter By Keyword

Filter By Attributes

Pediatric

Pediatric

MDR

HIV/TB

Filter By Country

None Specified

Filter By Sponsor

None Specified

Filter By Network

None Specified

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral doses of TMC207 in subjects with sputum-smear positive tuberculosis ([NCT00523926](#))
 Status: **Completed**
[View Details](#)

A Placebo-controlled, Phase 2 Trial to Evaluate OPC 67683 in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis (TB) ([NCT00523926](#))
 Status: **Completed**
[View Details](#)

Last Verified	Acronym	Type	Agent / Regimen	Sponsors	Study Chair / Lead
04/12/10	TMC207-C202	RX	Drug: OPC-67683 (total daily dose of OPC-67683 is 200 mg) for 56 days; Drug: OPC-67683 (total daily dose of OPC-67683 is 400 mg) 56 days; Drug: Placebo	Otsuka Pharmaceutical Development & Commercialization, Inc	Charles D. Wells, M.D.

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral doses of TMC207 in subjects with sputum-smear positive tuberculosis ([NCT00523926](#))
 Status: **Completed**
[View Details](#)

TMC207-C202: Study to Evaluate Bactericidal Activity of Multiple Oral doses of TMC207 in subjects with sputum-smear positive tuberculosis ([NCT00523926](#))
 Status: **Completed**
[View Details](#)

New Resource: CLINICAL TRIALS » TB DRUG TRIALS

Status:
Design complete
Assembling data
Under construction (Q1 2012)

Development partners:
Andrew Vernon / CDC,
Barbara Laughon / NIH/NIAID
and CPTR

Additional Site Enhancements

Delivering in Q4 2011 and Q1 2012

TARGETS

TARGETS FILTER

Filter By Keyword

Filter By Category

- DNA
- RNA
- Protein Synthase Inhibitors
- Cell Wall Inhibitors
- General TB Background Info
- Carbon Metabolism

Welcome to the Targets Database!

The purpose of the Targets database is to present current TB targets in a public forum and allow users to parse the list with ease. To view details of a target, [click the target name](#). To narrow down your search, you can enter a keyword or click the filter buttons to the left, which will dynamically filter the list of possible targets. If you find this database useful, please let us know at wand@newtbdrugs.org.

Isocitrate Lyase

Rv0467

GSK / TB Alliance Tres Cantos

orem Ipsum Dolor

Rv0467

Dolor Sit Amet

ea commodo consequa

Rv0467

Eros et accumsan

socitrate Lyase

Rv0467

GSK / TB Alliance Tres Cantos

orem Ipsum Dolor

Rv0467

Dolor Sit Amet

ea commodo consequa

Rv0467

Eros et accumsan

ea commodo consequa

Rv0467

Eros et accumsan

socitrate Lyase

Rv0467

GSK / TB Alliance Tres Cantos

orem Ipsum Dolor

Rv0467

Dolor Sit Amet

ea commodo consequa

Rv0467


Eros et accumsan

New Resource: Targets

Status:
Currently built
In the process of integrating data
Launch Q4 2011

Development partner:
Christopher Locher / Vertex

Click to view target details:



[Explore. Learn. Join the conversation.](#) Follow us on: [f](#) [in](#)

[Blog](#)
[Pipeline](#)
[About Us](#)
[Meetings](#)
[TB Resources](#)

[Discovery Pipeline](#)
[Pipeline](#)

[Add a Project](#)
[View Previous Pipelines](#)
[Register/Login to Pipeline](#)

TARGETS

← Return to Targets Overview

GSK / TB Alliance Tres Cantos

Last Updated: 11-Nov-2010

TARGET DESCRIPTION

Name
isocitrate lyase

EC number 4.1.3.1	Genbank accession CAESS284.1	Rv number Rv0467
-----------------------------	--	----------------------------

HAS THE TARGET BEEN VALIDATED? HOW?

Validated by Genetically (in vitro or in vivo)	PubMed References PMIDs or citations
--	--

Reagent Description

RECOMBINANT PROTEIN NAME / GENE ID	SOLUBLE?	FORMAT	PubMed REFERENCES
Rv0467-Sc013	Yes	November 2009	Completed

Assay Description (Target or Cell Based)

ASSAY NAME	READOUT	FORMAT	PubMed REFERENCES
My-isocitrate-lyase-assay	Fluorescence	November 2009	Completed
My Mtb cell phenotypic screen	Absorbance	Petri dish	PMIDs or citations

Compounds for Screening or Lead Optimization

LIBRARY NAME/IDENTIFIER	TOTAL # OF COMPOUNDS	SCREENED	HTS CUT OFF (ie. 40 um)	# OF HITS	# OF LEADS	PubMed REFERENCES
GSK Library	500,000	10000	40 um	10	0	PMIDs or citations
Rational design/fragment-based screening	50	40	40 um	3	1	PMIDs or citations

HITS OR LEADS

Chemical Class
Riminophenazines

NARRATIVE DESCRIPTION

No tractable hits emerged from enzymatic HTS against Icl1 and Icl2. High background of unannotated oxalate (Icl inhibitor) salts in commercial compounds

COUNTER-SCREEN ASSAY (Target or Cell Based)

Mammalian enzyme
E. coli or other species

CONTACT INFO

Jose-Luis Lavandera
jose-luis.d.lavandera@gsk.com
1-124-125-6789

Edit Target

© Working Group on New TB Drugs. All Rights Reserved.

Site by Darby Communications

[About](#)
[Contact Us](#)
[Privacy policy](#)

The Working Group is Supported By

PIPELINE > BIOLOGICS



CLINICAL DEVELOPMENT



PRECLINICAL DEVELOPMENT	PHASE I	PHASE II*	PHASE III
Lorem Ipsum Dolor  Sequella	Lorem Ipsum Dolor Lorem Ipsum Dolor	Continuar  Lorem Ipsum Dolor	Gatifloxacin Information provided by WGND
Lorem Ipsum  Sequella	Vocabularium Sommun paroles	Existentie  Lorem Ipsum Dolor	Moxifloxacin University College London
Existentie Quro Science, Inc.	Membres del Sam Lor separat	Vocabularium  Lorem Ipsum Dolor	Rifapentine Information provided by WGND
Existentie Quro Science, Inc.		Omnicos Lorem Ipsum Dolor	
Omnicos Quro Science, Inc.		Vocabularium  Lorem Ipsum	
Omnicos Quro Science, Inc.		Vocabularium Lorem Ipsum Dolor	



New Resource: **BIOLOGICS**

Status:

Design complete

Under construction

Launch (Q1 2012)

Development partner:

Christopher Locher / Vertex

Click to view biologics details:



[Explore. Learn. Join the conversation.](#) Follow us on: [f](#) [in](#)

[Blog](#)
[Pipeline](#)
[About Us](#)
[Meetings](#)
[TB Resources](#)

[Discovery Pipeline](#)
[Pipeline](#)

[Add a Project](#)
[View Previous Pipelines](#)
[Register/Login to Pipeline](#)

PIPELINE > BIOLOGICS

Product/Compound Name

Last Updated: 11-Nov-2010

PRODUCT PROFILE

Potential
Will be inexpensive, scalable, available for production. This text could go on to a second line or more as needed.

Potential Biomarkers
Decreased IL-4, decreased TNF-alpha. This text could go on to a second line or more as needed.

Therapeutic Goal
Clinical improvement / survival, STSC

Initial Target Population
+/- MDR, +/- HIV

CONCERNS AND RECOMMENDATIONS

Toxicity
NK (cardiotoxicity for COX2 inhibitors).

Next Step
Complete GMP production.

Additional Description
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam, quis nostrud exerci tation ullamcorper

ADMINISTRATION AND HANDLING

DOSE	ROUTE	SCHEDULES	COLD CHAIN	STORAGE
1mg	Oral Dosing	Multiple 5 daily doses every six weeks.	Yes	>1 yr at +4°C and 3 months

RELATED LINKS
[This is the first link text.](#)
[This is another link.](#)
[This is yet another related link to this particular product or compound.](#)

CONTACT INFO
 Jose-Luis Lavandera
jose-luis.d.lavandera@gsk.com
 1-124-125-6789

EVALUATIONS
 Preclinical Tax: Not completed
 Phase I Safety: not established
 Phase I/II preliminary efficacy: yes

© Working Group on New TB Drugs. All Rights Reserved.

Site by Darby Communications

[About](#)
[Contact Us](#)
[Privacy policy](#)

The Working Group is Supported By

MEETINGS

"Essentiality of PZA" Workshop

May 31 - June 1, Bethesda, Maryland

MEETING OVERVIEW

DAY 1
May 31, 2011 7:00 p.m. - 10:00 p.m.
Working Dinner with Special Presentations by Jacques Grosset and Oren Zimhony
Bethesda Marriott | 6711 Democracy Boulevard | Bethesda, Maryland 20817

DAY 2
June 1, 2011 8:15 a.m. to 4:30 p.m.
Essentiality of PZA Workshop
NIH/NIAD | 6610 Rockledge Drive, Room 4008 | Bethesda, Maryland 20817-1811

Day 1

May 31, 2011

SPEAKERS & ATTENDEES

Ammerman, Nicole
Center for Tuberculosis Research
Dept. of Medicine, Div. of Infectious Diseases
Johns Hopkins School of Medicine

Bao, Jing
Tuberculosis Clinical Research Team
Division of AIDS, NIAID, NIH, DHHS

Baughn, Anthony
Department of Microbiology
University of Minnesota

Bishai, William
Center for Tuberculosis Research
Director, KwaZulu-Natal Research Institute for
Tuberculosis and HIV (K-RITHT)
Dept. of Medicine, Div. of Infectious Diseases
Johns Hopkins School of Medicine

Blanchard, John
Albert Einstein College of Medicine

Boshoff, Helena
Tuberculosis Research Section, LCID, NIAID,
NIH, DHHS

Deininger, David
Vertex Pharmaceuticals Incorporated

Farhat, Maha
Department of Pulmonary and Critical Care
Medicine, Massachusetts General Hospital

Grosset, Jacques
Center for Tuberculosis Research
Dept. of Medicine, Div. of Infectious Diseases
Johns Hopkins School of Medicine

Hafner, Richard
Division of AIDS, NIAID, NIH, DHHS

Jacobs, William
Department of Microbiology & Immunology
Albert Einstein College of Medicine
Michael F. Price Center

Lacourclere, Karen
Respiratory Disease Branch, NIAID, NIH,
DHHS

Laughon, Barbara
Division of Microbiology and Infectious
Diseases, NIAID, NIH

Lenaerts, Anne
Department of Microbiology, Immunology and
Pathology
Colorado State University

DOWNLOADS

 [Full Agenda \[160kb\]](#)

 [Next Steps Plan \[96kb\]](#)

For more information
regarding the Next Steps
Plan, please contact:
[Richard Hafner](#) or [Jing Bao](#)

DINNER

Special Presentation

Jacques Grosset

[Download Presentation \[2,200kb\]](#)



Video coming soon!

Special Presentation

Oren Zimhony

[View Synopsis](#) [Download Presentation \[2,300kb\]](#)



Video coming soon!

Day 2

June 1, 2011

SESSION 1

What Mice Tell Us About the Essentiality of PZA

Eric Nuermberger

[View Synopsis](#) [Download Presentation \[608kb\]](#)



Click to play

New aspects of the activity of PZA

John Welch

[Download Presentation \[10,200kb\]](#)



Click to play

Does pyrazinamide have a host-directed mechanism of action?

Nicole Ammerman

[View Synopsis](#) [Download Presentation \[680kb\]](#)



Click to play

SESSION 2

Pyrazinamide treatment prevents the clinical signs of cutaneous leishmaniasis

Susana Mendez

[View Synopsis](#) [Download Presentation \[6,300kb\]](#)



Click to play

What do we know about the intracellular environment experienced by *M. tuberculosis*?

David Russell

[View Synopsis](#) [Download Presentation \[18,900kb\]](#)



Click to play

nad biosynthetic mutants of *Mycobacterium tuberculosis*: a tool to elucidate PZA action

Catherine Vlicheze & William Jacobs

[View Synopsis](#) [Download Presentation \[1,200kb\]](#)



Click to play

SESSION 3

New Resource: MEETING RECAPS

Launched with
PZA Workshop
(DC / May 31 – June 1)

Features:

- presentations
- video presentations
- agenda
- speakers / attendees

[View Synopsis](#)
[Download Presentation \[608kb\]](#)



New aspects of the activity of PZA
John Welch


[Download Presentation \[10,200kb\]](#)


Does pyrazinamide have a host-directed mechanism of action?
Nicole Ammerman


[View Synopsis](#)
[Download Presentation \[680kb\]](#)


SESSION 2

Pyrazinamide treatment prevents the clinical signs of cutaneous leishmaniasis
Susana Mendez


[View Synopsis](#)
[Download Presentation \[6,300kb\]](#)

What do we know about the intracellular environment experienced by *M. tuberculosis*?
David Russell


[View Synopsis](#)
[Download Presentation \[18,900kb\]](#)


nad biosynthetic mutants of *Mycobacterium tuberculosis*: a tool to elucidate PZA action
Catherine Vilcheze & William Jacobs


[View Synopsis](#)
[Download Presentation \[1,200kb\]](#)


SESSION 3

In search of parsimony: An alternative hypothesis for the mode of action of pyrazinamide
Anthony Baughn


[View Synopsis](#)
[Download Presentation \[764kb\]](#)

Pyrazinamide, sterilizing drug only?
Jacques Grosset


[View Synopsis](#)
[Download Presentation \[140kb\]](#)

Efficacy of PZA administered as a single drug in various TB mouse infection models (GKO, Balb/c and Kramnik)
Anne Lenaerts


[Download Presentation \[13,400kb\]](#)

SESSION 4

The Roller Coaster of PZA
Ying Zhang


[View Synopsis](#)
[Download Presentation \[5,700kb\]](#)

Discovery of a new generation pyrazinamide
Zhenkun Ma


[View Synopsis](#)
[Download Presentation \[1,200kb\]](#)

NEXT STEPS

Overview of Planned NIH Sponsored PZA Workshop scheduled for Spring 2012
Richard Hafner

[View Synopsis](#)

Boshoff, Helena
 Tuberculosis Research Section, LCID, NIAID, NIH, DHHS

Deininger, David
 Vertex Pharmaceuticals Incorporated

Farhat, Maha
 Department of Pulmonary and Critical Care Medicine, Massachusetts General Hospital

Grosset, Jacques
 Center for Tuberculosis Research
 Dept. of Medicine, Div. of Infectious Diseases
 Johns Hopkins School of Medicine

Hafner, Richard
 Division of AIDS, NIAID, NIH, DHHS

Jacobs, William
 Department of Microbiology & Immunology
 Albert Einstein College of Medicine
 Michael F. Price Center

Lacourciere, Karen
 Respiratory Disease Branch, NIAID, NIH, DHHS

Laughon, Barbara
 Division of Microbiology and Infectious Diseases, NIAID, NIH

Lenaerts, Anne
 Department of Microbiology, Immunology and Pathology
 Colorado State University

Locher, Christopher
 Vertex Pharmaceuticals Incorporated

Ma, Zhenkun
 TB Alliance

Makhene, Mamodikoe
 Division of Microbiology and Infectious Diseases, NIAID, NIH, DHHS

Mendez, Susana
 Baker Institute for Animal Health
 Cornell University

Nuernberger, Eric
 Dept. of Medicine, Div. of Infectious Diseases
 Johns Hopkins School of Medicine

Russell, David
 Microbiology and Immunology
 College of Veterinary Medicine
 Cornell University

Scott, Cherise
 Working Group on New TB Drugs

Sizemore, Christine
 Respiratory Disease Branch, NIAID, NIH, DHHS

Spigelman, Mel
 TB Alliance

Vilcheze, Catherine
 Department of Microbiology & Immunology
 Albert Einstein College of Medicine

Welch, John
 Chemistry
 College of Arts and Sciences
 University of Albany

Zhang, Ying
 Molecular Microbiology and Immunology
 Johns Hopkins Bloomberg School of Public Health

Zimhony, Oren
 Division of Infectious Diseases
 Kaplan Medical Center Rehovot
 Hebrew University and Hadassah

New Resource:
MEETING RECAPS

COMPREHENSIVE!

RESOURCE CATALOG

Search

TB Research and Drug Development
[Researchers](#)
[Preclinical](#)
[Microbial markers](#)
[Imaging studies](#)
Networks
[Research Groups_Institutes](#)
[Donor Agencies_Organizations](#)
[Pharmaceutical Companies](#)

TB Research Tools
[Animal Models](#)
[Drug Discovery](#)
[Genetics](#)
[Kits](#)
[Structure](#)
[Targets](#)

Community Engagement and Advocacy
[Interactive Tools](#)
[TB Knowledge Links](#)

WELCOME TO THE WGND'S
TB RESOURCES



CLICK TO THE LEFT TO LOOK AT SPECIFIC RESOURCE CATEGORIES OR SEARCH USING KEYWORDS

Enhanced Resource: TB RESOURCE CATALOG

Status:
Fully operational
Integrating Data (Q4 2011)

Development partner:
Gerhard Walzl / Stellenboch

RESOURCES » GRANTS FINDER

In keeping with our missions to help speed the development of new drugs for the treatment of tuberculosis, we have created this tool to help people locate grants that might be appropriate for their work.

Please click on the subject areas below to filter the available grants.

Filter by Category

Funding Purpose

- Advocacy
 - Event
 - Implementation
 - Individual Awards
 - Research
- #### Type of Funder
- Foundation
 - Government
 - Non-Profit/NGO

Filter by Amount

- \$10,000 - \$50,000
- \$51,000 - \$100,000
- \$101,000 - \$250,000
- \$251,000 - \$500,000
- \$501,000 - \$1,000,000
- \$1,000,000+

Restrict to a Single Geographic Area

- Africa
- Europe
- UK
- USA

Structural Genomics Centers for Infectious Diseases (NIAID-DMID-NIHAI2011124)

Grantor: National Institutes of Health (NIH) (Deadline: 11/07/2011)

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases, has a requirement for a Structural Genomics Research Program.

Round 8 of Grand Challenges Explorations

Grantor: Bill & Melinda Gates Foundation (Deadline: 11/17/2011)

Grand Challenges Explorations fosters innovation in global health research. The Bill & Melinda Gates Foundation has committed \$100 million to encourage scientists worldwide to expand the pipeline of ideas to fight our greatest health challenges.

Round 11 Funding Cycle

Grantor: Global Fund to Fight AIDS, Tuberculosis and Malaria (Deadline: 12/15/2011)

The Global Fund provides grants in support of technically sound and cost-effective interventions for the prevention of infection and the treatment, care and support of persons infected and directly affected by HIV/AIDS, tuberculosis and malaria.

Open Letters of Inquiry for Tuberculosis

Grantor: Bill & Melinda Gates Foundation (Deadline: ongoing)

We support the mission and goals of the *World Health Organization's Stop TB Partnership*. The goal of this plan is to treat 50 million people with TB and prevent 14 million deaths in the next decade. We're working to ensure that better drugs, diagnostics, and vaccines are developed and made accessible to those who need them the most.

Host-Targeted Interventions as Therapeutics for Infectious Diseases (R21/R33)

Grantor: National Institutes of Health (NIH) (Deadline: 11/30/2011)

Development of new, safe and effective therapeutics for infectious diseases is a high priority. This initiative seeks to stimulate innovation in the discovery and development of therapeutics that target host-encoded functions required for infection, replication, spread and/or pathogenesis by one or more NIAID Category A, B, or C priority pathogens <http://www.niaid.nih.gov/topics/BiodefenseRelated/Biodefense/research/Pages/CatA.aspx>, and potentially, additional non-listed pathogens.

The MRC/DfID African Research Leader scheme

Grantor: Medical Research Council (MRC) and UK's Department for International Development (DfID) (Deadline: 11/03/2011)

Following a pilot call last year, the Medical Research Council has now launched "a second call to support African Research Leaders. This is a prestigious award, jointly funded by the MRC and the UK's Department for International Development (DfID), for non-clinical and clinical researchers of exceptional ability. The aim of the scheme is to strengthen research leadership across sub-Saharan Africa, by attracting and retaining researchers of high ability. The call has been re-focused this year on 'rising star' African Research Leaders."

Enhanced Resource: TB GRANTS FINDER

Status:

Fully operational

Looking for partners to help populate with fresh data

Will be adding a form to submit grants data



Explore. Learn.

Join the conversation.